News of Note—Altimmune’s new CEO, Scripps’ HIV vaccine and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Altimmune has poached Neos Therapeutics’ CEO, Vipin Crag, Ph.D., to succeed Bill Enright as its president and CEO. Release

> Scripps Research scientists have found a way to stabilize HIV envelope protein for a new HIV vaccine. The candidate elicited robust anti-HIV antibody responses in mice and rabbits, the team reported. Release

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> The NIH awarded Tulane University School of Medicine a contract worth up to $8.5 million to develop a more effective and longer-lasting vaccine against whooping cough. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.